Design Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

內部人士正在買入Design Therapeutics和其他2只低於5美元的股票

Benzinga · 03/26 19:37

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

FTC Solar

The Trade: FTC Solar, Inc. (NASDAQ:FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930.
What's Happening: On March 13, FTC Solar posted upbeat quarterly sales.
What FTC Solar Does: FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services.

Ocuphire Pharma

The Trade: Ocuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri acquired a total of 10,000 shares at at an average price of $2.10. To acquire these shares, it cost around $21,000. The company's COO Joseph K Schachle also bought 2,000 shares.
What's Happening: On March 8, Ocuphire Pharma posted fourth-quarter sales of $1.700 million.
What Ocuphire Pharma Does: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

Design Therapeutics

The Trade: Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid acquired a total of 26,965 shares at an average price of $3.70. The insider spent around $99,738 to buy those shares. The company'd Director Heather A. Berger also bought 1,300 shares.
What's Happening: On March 19, Design Therapeutics posted a narrower-than-expected quarterly loss.
What Design Therapeutics Does: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

Don't forget to check out our premarket coverage here

The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道瓊斯指數週一收盤下跌超過150點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是近期一些值得注意的細價股內幕交易。欲了解更多，請查看 本辛加的內幕交易 平台。

FTC Solar

FTC Solar

The Trade: FTC Solar, Inc. (NASDAQ:FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930.
What's Happening: On March 13, FTC Solar posted upbeat quarterly sales.
What FTC Solar Does: FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services.

交易：聯邦貿易委員會太陽能公司（納斯達克股票代碼：FTCI）董事艾哈邁德·查蒂拉 共收購了92,600股股票 平均價格爲0.55美元。收購這些股票的成本約爲50,930美元。
發生了什麼：3月13日，聯邦貿易委員會太陽能公佈了樂觀的季度銷售額。
聯邦貿易委員會太陽能公司的作用：FTC Solar Inc是太陽能跟蹤系統的提供商，由專有軟件和增值工程服務提供支持。

Ocuphire Pharma

Ocuphire Pharma

The Trade: Ocuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri acquired a total of 10,000 shares at at an average price of $2.10. To acquire these shares, it cost around $21,000. The company's COO Joseph K Schachle also bought 2,000 shares.
What's Happening: On March 8, Ocuphire Pharma posted fourth-quarter sales of $1.700 million.
What Ocuphire Pharma Does: Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

交易：Ocuphire Pharma, Inc.（納斯達克股票代碼：OCUP）首席財務官尼拉夫·賈維裏 共收購了 10,000 股股票 平均價格爲2.10美元。收購這些股票的成本約爲21,000美元。該公司的首席運營官約瑟夫·沙赫爾也購買了2,000股股票。
發生了什麼：3月8日，Ocuphire Pharma公佈了第四季度銷售額爲17億美元。
Ocuphire Pharma做什麼：Ocuphire Pharma Inc是一家臨床階段的眼科生物製藥公司，專注於開發和商業化治療屈光和視網膜眼病的療法。

Design Therapeutics

設計療法

The Trade: Design Therapeutics, Inc. (NASDAQ:DSGN) Director John P. Schmid acquired a total of 26,965 shares at an average price of $3.70. The insider spent around $99,738 to buy those shares. The company'd Director Heather A. Berger also bought 1,300 shares.
What's Happening: On March 19, Design Therapeutics posted a narrower-than-expected quarterly loss.
What Design Therapeutics Does: Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

貿易：Design Therapeutics, Inc.（納斯達克股票代碼：DSGN）董事約翰·施密德 共收購26,965股股票 平均價格爲3.70美元。知情人士花費了約99,738美元購買了這些股票。該公司的董事希瑟·伯傑還購買了1300股股票。
發生了什麼：3月19日，Design Therapeutics公佈的季度虧損低於預期。
Design Therapeutics做什麼：Design Therapeutics Inc是一家臨床階段的生物製藥公司，從事GenetaCTM分子的研究和開發，這些分子是一種新型的小分子基因靶向嵌合體候選療法，旨在通過解決遺傳性核苷酸重複擴張突變引起的疾病的根本原因來改善疾病。

Don't forget to check out our premarket coverage here

別忘了在這裏查看我們的上市前報道

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。